The drugmaker, already struggling to cut costs in order to meet debt repayments, may face billions of dollars in fines

Israeli generic drug manufacturer named as 'consistent participant' in conspiracies to raise prices, sometimes by more than 1000%; executives said to have obstructed investigation

Reuters: World’s largest generic drugmaker earned 60 cents per diluted share, down from 94 cents a year earlier; says on track to cut $3 billion in costs by the end 2019

Israeli pharmaceutical company gets OK from US regulators for its version of Narcan